ORIGINAL ARTICLE
The role of pathologists in recognition of morphologic and biologic features of genetically mutated breast cancer
This article has the following note(s):
-
NOTIFICATION: The Role of Pathologists in Recognition of Morphologic and Biologic Features of Genetically Mutated Breast Cancer
- Volume 2025Issue 1The Breast Journal
- First Published online: January 13, 2025
Shahla Masood MD,
Corresponding Author
Shahla Masood MD
Department of Pathology and Laboratory Medicine, University of Florida College of Medicine – Jax, Jacksonville, Florida, USA
Correspondence
Shahla Masood, Department of Pathology and Laboratory Medicine, University of Florida College of Medicine – Jax, 655 W. 8th St, Jacksonville, FL 32209.
Email: [email protected]
Search for more papers by this authorShahla Masood MD,
Corresponding Author
Shahla Masood MD
Department of Pathology and Laboratory Medicine, University of Florida College of Medicine – Jax, Jacksonville, Florida, USA
Correspondence
Shahla Masood, Department of Pathology and Laboratory Medicine, University of Florida College of Medicine – Jax, 655 W. 8th St, Jacksonville, FL 32209.
Email: [email protected]
Search for more papers by this authorAbstract
The recent introduction of genomic medicine and emphasis on optimizing breast cancer risk reduction mortalities has provided opportunities for pathologists to partner with clinicians in advancing the diagnosis and management of breast cancer patients. The discovery of breast cancer genes BRCA1, BRCA2, and other breast cancer genes is considered a major breakthrough in the understanding of hereditary breast cancer. These discoveries have contributed to investigate the nature of tumorigenesis and the genetic and molecular pathology in multistep tumor development, as well as their relationship to endocrine and environmental factors. The recognition of unique morphologic and biological features associated with genetically mutated breast cancer by pathologists may have an impact on appropriate follow-up management of breast cancer patients.
REFERENCES
- 1 Broca. Traite des tumeurs, 1866.
- 2Claus EB, Schildkraut J, Iversen ES, Berry D, Parmigiani G. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst. 1998; 90: 1824-1829.
- 3 Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a populatin-based series of breast cancer cases. Br J Cancer. 2000; 83(10): 1301-1308.
- 4Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266: 66-71.
- 5Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995; 378: 789-792.
- 6Da Silva L, Lakhani SR. Pathology of hereditary breast cancer. Modern Path. 2010; 23: 546-551.
10.1038/modpathol.2010.37 Google Scholar
- 7Eby N, Chang-Claude J, Bishop DJ. The familial and genetic susceptibility for breast cancer. Cancer Causes Control. 1994; 5: 458-470.
- 8Narod SA, Ford DA, Devilee P, et al. An evaluation of genetic heterogeneity in 145 breast ovarian cancer families. Breast cancer linkage consortium. Am J Hum Genet. 1995; 36: 254-264.
- 9Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985; 312: 146-151.
- 10Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994; 265: 2088-2090.
- 11Easton D, Ford D, Peto J. Inherited susceptibility to breast cancer. Cancer Surv. 1993; 18: 95-113.
- 12Lynch ED, Ostermeyer EA, Lee MK, et al. Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet. 1997; 61: 1254-1260.
- 13Mckinnon PJ. ATM and ataxia telangiectasia. EMBO Rep. 2004; 5: 772-776.
- 14Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene. 2006; 25: 5912-5919.
- 15Rahman N, Scott RH. Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Hum Mol Genet. 2007; 16(Spec No. 1): R60-R66.
- 16Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007; 39: 165-167.
- 17Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet. 2008; 40: 17-22.
- 18Simard J, Tonin P, Durocher F, et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet. 1994; 8: 392-398.
- 19Johannsson O, Ostermey EA, Hakansson S, et al. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet. 1996; 58: 441-450.
- 20Thorlacius S, Olafsdottir G, Tryggvadottir L, et al. A Single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996; 13: 117-119.
- 21Gayther SA, Harrington P, Russell P, et al. Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia. Am J Hum Genet. 1997; 60: 1239-1242.
- 22Inoue R, Fukutomi T, Ushijima T, Matsumoto Y, Sugimura T, Nagno M. Germline mutation of BRCA1 in Japanese breast cancer families. Cancer Res. 1995; 55: 3521-3524.
- 23Bar-Sade RB, Kruglikova A, Modan B, et at. The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. Hum Mol Genet. 1998; 7: 801-805.
- 24Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003; 39: 214-221.
10.1093/jnci/95.3.214 Google Scholar
- 25Iscovich J, Abdulrazik M, Cour C, Fischbein A, Peer J, Goldgar DE. Prevalence of the BRCA2 6174 del T mutation in Israeli uveal melanoma patients. Int J Cancer. 2002; 98: 42-44.
- 26Kirchhoff T, Kauff ND, Mitra K, et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res. 2004; 10: 2918-2921.
- 27Narod SA, Feunteun J, Lynch HT, et al. Familial breast-ovarian cancer locus on chromosome 17q12-123. Lancet. 1991; 338: 82-83.
- 28Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst. 2004; 96: 15-21.
- 29Zweemer RP, van Diest PJ, Verheijen RH, et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol. 2000; 76: 45-50.
- 30Lakhani SR, Easton DF, Stratton MR, et al. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer linkage Consortium. Lancet. 1997; 349: 1505-1510.
- 31Armes JE, Egan AJ, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer. 1998; 83: 2335-2345.
10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N CAS PubMed Web of Science® Google Scholar
- 32Lakhani SR. The pathology of familial breast cancer: morphological aspects. Breast Cancer Res. 1999; 1: 31-35.
- 33Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998; 90: 1138-1145.
- 34Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005; 11: 5175-5180.
- 35Hoogerbrugge N, Bult P, de Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breast from women at hereditary risk for breast cancer. J Clin Oncol. 2003; 21: 41-45.
- 36Armes JE, Trute L, White D, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 1999; 59: 2011-2017.
- 37Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in pathients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002; 20: 2310-2318.
- 38Marcus JN, Watson P, Page DL, Lynch HT. Pathology and heredity of breast cancer in younger women. J Natl Cancer Inst Monogr. 1994; 86: 23-34.
- 39Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer. 1996; 77: 697-709.
10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W CAS PubMed Web of Science® Google Scholar
- 40Palacios J, Honrado E, Osorio A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res. 2003; 9(10 Part 1): 3606-3614.
- 41Quenneville LA, Phillips KA, Ozcelik H, et al. Her-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer. 2002; 95: 2068-2075.
- 42Freneaux P, Stoppa-Lyonnet D, Mouret E, et al. Low expression of bcl-2 in BRCA1-associated breast cancer. Br J Cancer. 2000; 83: 1318-1322.
- 43Vaziri SA, Tubbs RR, Darlington G, et al. Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. Mol Pathol. 2001; 54: 259-263.
- 44Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004; 64: 830-835.
- 45Palacios J, Honrado E, Osorio A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res. 2003; 9: 3606-3614.
- 46Lynch BJ, Holden JA, Buys SS, Neuhausen SL, Gaffney DK. Pathobiologic characteristics of hereditary breast cancer. Hum Pathol. 1998; 29: 1140-1144.
- 47Crook T, Brooks LA, Crossland S, et al. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1 and BRCA2 associated breast tumours. Oncogene. 1998; 17: 1681-1689.
- 48Phillips KA, Nichol K, Ozcelik H, et al. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J Natl Cancer Inst. 1999; 91: 469-473.
- 49Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S. Acceleration of chromosomal instability of BRCA1-associated hereditary breast cancers by p53 abnormality. Breast J. 2002; 8(2): 77-80.
- 50Peron C, Sorlie T, Eisen M, et al. Molecular portraits of human breast tumors. Nature. 2000; 406(6797): 747-752.
- 51Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003; 100(14): 8418-8423.
- 52Palacios J, Honrado E, Osorio A, et al. Germline BRCA 1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2004; 96: 712-714; author reply 714.
- 53Foulkes WE, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003; 95: 1482-1485.
- 54Lakhani SR, Gusterson BA, Jacquemier J, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res. 2000; 6: 782-789.
- 55Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007; 9: R4.
- 56Gaedcke J, Traub F, Milde S, et al. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Mod Pathol. 2007; 20: 864-870.
- 57Masood S. The clinical significance of recognizing distinct morphologic and biological features of hereditary breast cancer. Breast J. 2003; 9(2): 67-70.
